5432132026-01-012026-03-315432132026-03-315432132025-03-315432132025-04-012026-03-315432132026-01-012026-03-31in-capmkt:OtherExpenses1Member5432132025-04-012026-03-31in-capmkt:OtherExpenses1Member5432132026-03-31OtherNoncurrentFinancialAssetsDomain15432132026-03-31OtherNoncurrentAssetsDomain15432132026-03-31OtherNoncurrentAssetsDomain25432132026-03-31OtherCurrentFinancialAssetsDomain15432132026-03-31OtherCurrentAssetsDomain15432132026-03-31OtherNoncurrentFinancialLiabilitiesDomain15432132026-03-31OtherCurrentFinancialLiabilitiesDomain15432132026-03-31OtherCurrentFinancialLiabilitiesDomain25432132026-03-31OtherCurrentLiabilitiesDomain15432132026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15432132025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15432132026-01-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15432132025-04-012026-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15432132026-01-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares543213ROSSARINOTLISTEDINE02A801020ROSSARI BIOTECH LIMITEDMain BoardEquity2025-04-012026-03-312026-04-272026-04-18INRMillionsQuarterlyFourth quarterSingle segmentManufacturing of Specialty Chemicals for Textile, Home and Personal Care, Performance Chemicals and Animal Health and Nutrition industries2026-04-2714:00:002026-04-2715:45:00trueCash Flow IndirectDeclaration of unmodified opinion2026-01-012026-03-31AuditedConsolidated6848620000190650000703927000044446800002409700002715800003922800009059000023528000072660000064019800006372900000637290000159150000236100001827600000454530000000514000045967000062000004658700004596700000465870000011077000028.38.29008.38.29Notes:1.The financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meeting held on 27th April, 2026.2.The consolidated financial results have been prepared in accordance with the recognition and measurement principles laid down under Indian Accounting Standards (Ind AS), as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.3.The consolidated financial results include the financial results of four foreign subsidiaries - Rossari Global FZCO (formerly known as Rossari Global DMCC), Rossari Bangladesh Limited, Rossari International Company Limited and Rossari (Singapore) Pte Ltd (incorporated on 18th December 2025), two step-down foreign subsidiaries - Rossari Biotech Trading FZE and Unistar Thai Co. Ltd. (100% subsidiary of Rossari Global FZCO), four Indian subsidiaries - Unitop Chemicals Private Limited, Tristar Intermediates Private Limited, Buzil Rossari Private Limited and Rossari Consumer Products Private Limited, an associate company - Romakk Chemicals Private Limited and a joint venture company - Hextar Unitop SDN. BHD. (a joint venture company of Unitop Chemicals Private Limited).4.The Group deals in Specialty chemicals and considering that the nature of products and the predominant risk and returns of the products are similar, the Group considers it as one operating segment.5.The figures for the quarter ended 31st March, 2026 and 31st March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures upto nine months of the relevant financial year.6.During the quarter ended 31st March, 2026, the Parent Company has sold its Kanjurmarg Office for a consideration of Rs. 250 million. Consequently, the Company has recognised a gain of Rs. 192.67 million (net) under the head ‘Other Income’ in the Statement of Profit and Loss.7.During the quarter ended 31st March, 2026, the Parent Company has allotted 2,000 equity shares of Rs. 2 each pursuant to exercise of options under the approved Rossari Employee Stock Option Plan - 2019.8."The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes, viz., Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 (Collectively referred to as the ‘New Labour Codes’). These codes have been made effective from 21st November, 2025.The Group has estimated the revised gratuity liability as at 31st December 2025 and as at 31st March 2026 as per the New Labour Codes and the additional liability arising thereon has been recognized as part of employee benefit expenses in the current reporting period. No material additional liability on compensated absences and provident fund arose on account of the aforesaid codes.The Government is in the process of notifying related rules to the New Labour Codes and impact of these will be evaluated and accounted for in accordance with applicable accounting standards in the period in which they are notified." <BR> 9.The Board of Directors have recommended final dividend of Re.0.50 (25 percent of the face value of the equity share of Rs. 2 each) for the financial year ended 31st March, 2026. <BR> 10.Previous year / period figures have been regrouped to make them comparable with the current year / period figures, wherever applicable, which are not material. <BR> For ROSSARI BIOTECH LIMITED <BR> EDWARD MENEZES <BR> Executive Chairman <BR> DIN:00149205 <BR> Place:Mumbai <BR> Date:27th April,20262025-04-012026-03-31AuditedConsolidated239636500002237800002418743000016036780000934150000-2836600001547480000285430000791240000286987000022181290000200614000002006140000612790000-7977000053302000001473120000000190100001492130000760000149289000014921300000149289000001107700002026.9526.930026.9526.93Other Expenses726600000Other Expenses28698700005605380000173301000011871100001052020000269820000212000008848000090600000149430000363780000104511500004045450000351000000557413000075307000016907000011530000591600006917960000139559000012359000000777700002288792000011077000013222720000133334900001333349000094326000000020253000011457900008260000043046000001658850000313660000035853000028759900003234520000123705000076081700001141800008323000090000000789558000000955443000022887920000Other Financial Assets88480000Income Tax Assets (Net)119790000Other non-current assets243990000Other Financial assets59160000Other current assets1395590000Lease Liabilities202530000Lease Liabilities76980000Other Financial Liabilities1160070000Other current liabilities114180000272470000-494640000-1349140000000000305230000000791240000011760000000-232800000135100003330000000-204560000032500000-66788000013382600000006875800000650680000002311800000000024174000026467200000000000000000000011950000148600000-47820000-21948100000083300000000023957000001955600006598000027680000251590000001863220000319090000-8040000311050000442020000753070000Remeasurements of the defined benefit plans1124000011240000Remeasurements of the defined benefit plans186000018600002830000470000Exchange difference on translation of foreign operations-2950000-2950000Exchange difference on translation of foreign operations-840000-840000-740000-2100006200000760000AuditedtrueWalker Chandiok & Co LLPtrue2028-05-31